Abstract:Introduction The prevalence of obesity and related disorders is rapidly rising due to altered food habits, sedentary lifestyles and stress. Adipose tissue releases various hormones known as adipokines; one example is chemerin, which is primarily expressed by hepatocytes, adipocytes, and immune cells. Adipokine dysregulation in obesity initiates the cascade of inflammation and insulin resistance that leads to various metabolic disorders such as diabetes mellitus, metabolic syndrome (MS), and metabolic dysfunction-associated fatty liver disease (MAFLD). Aim The aim of our research is to determine serum chemerin levels in obese and non-obese individuals and to estimate the prevalence of MAFLD in obesity. Materials and methods This cross-sectional study was conducted at SRM Medical College Hospital & Research Centre, Tamil Nadu from August 2023 to December 2023. The study group comprised 45 obese and 45 non-obese individuals above 18 years of age. New MAFLD diagnostic criteria and FLI (Fatty Liver Index) formula were used to stratify the cohort. The Godin Leisure-Time Exercise questionnaire was used to assess physical activity levels. Visceral fat was assessed using a body composition analyzer. Student's t-test and ANOVA were used to compare the difference in mean levels across the groups. Pearson's correlation was used to correlate the analyzed parameters. Results Among our obese study participants, nearly 50% reported following a sedentary lifestyle. The prevalence of MAFLD in our obese study group was 44% whereas the prevalence of non-alcoholic fatty disease was found to be only 33%. Fasting plasma glucose (FPG), HbA1c, triglycerides (TG) and chemerin levels were found to vary significantly between the two groups. However, our study did not reveal the association of chemerin with MAFLD, BMI, or visceral fat in obesity. A significant difference in BMI, and visceral fat was observed across groups stratified by their physical activity levels assessed using the Godin leisure questionnaire. Conclusion Our study highlights the effect of physical activity on adipose tissue distribution and metabolic health and does not reveal any significant association of chemerin with MAFLD, BMI, or visceral fat in obesity. Nearly half of the studied obese individuals lead sedentary lifestyles, which highlights the importance of promoting physical activity in the prevention of obesity and related metabolic dysfunction. To validate these findings, future research should involve larger, diverse cohorts and include longitudinal data to track shifts in chemerin levels over time and their impact on metabolic health.

Chemerin in Obese Patients with Nonalcoholic Fatty Liver Disease with or without Prediabetes

Independent Association of Circulating Level of Chemerin With Functional and Early Morphological Vascular Changes in Newly Diagnosed Type 2 Diabetic Patients

Circulating Chemerin Levels in Obese and Non-obese Individuals and Its Association With Obesity in Metabolic Dysfunction-Associated Fatty Liver Disease

Chemerin Levels in Individuals with Type 2 Diabetes and a Normal Weight versus Individuals with Type 2 Diabetes and Obesity: An Observational, Cross-Sectional Study

Circulating chemerin levels in metabolic-associated fatty liver disease: a systematic review and meta-analysis

Is Chemerin Associated with Gestational Diabetes Mellitus? an Evidence-Based Clinical Research from Chinese Women

The association of serum chemerin level with risk of coronary artery disease in Chinese adults

Chemerin is Associated with Inflammatory Markers and Metabolic Syndrome Phenotypes in Hypertension Patients.

Elevating circulation chemerin level is associated with endothelial dysfunction and early atherosclerotic changes in essential hypertensive patients

Circulating chemerin level and the risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis

Serum vitamin D levels are inversely related with non-alcoholic fatty liver disease independent of visceral obesity in Chinese postmenopausal women.

Serum Lipocalin-2, Cathepsin S and Chemerin Levels and Nonalcoholic Fatty Liver Disease

The Role of Chemerin in Metabolic and Cardiovascular Disease: A Literature Review of Its Physiology and Pathology from a Nutritional Perspective

Remnant Cholesterol and Severity of Nonalcoholic Fatty Liver Disease.

New Utility of an Old Marker: Serum Low-Density Lipoprotein Predicts Histopathological Response of Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer.

Determinants of elevated chemerin as a novel biomarker of immunometabolism: data from a large population-based cohort

Chemerin, TNF - α and the degree of albuminuria in patients with diabetic kidney disease

The Chemerin-CMKLR1 Axis is Functionally important for Central Regulation of Energy Homeostasis

A Cross-Sectional Study: Systematic Quantification of Chemerin in Human Cerebrospinal Fluid

Impacts of Chemerin Levels and Antioxidant Capacity on the Severity of Cardiovascular Autonomic Neuropathy in Patients with Type 2 Diabetes and Prediabetes

Chemerin Levels in COVID-19 Are More Affected by Underlying Diseases than by the Virus Infection Itself